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INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem genetic disorder
characterized by benign tumors in multiple organs, including the skin, brain, kidneys, and lungs
and occasional malignant tumors. Hamartomas in the brain, retina, and sometimes other organs
also occur (1–3). The estimated prevalence is 1:600–1:10,000 live births in the general population
(4–6). Patients present at different ages with different manifestations, and varying degrees of organ
involvement (Figure 1). CNS manifestations of TSC mainly present in childhood, affect around
85% of patients (8), frequently resulting in epilepsy refractory to treatment, intellectual impairment,
autistic spectrum disorder, attention deficit hyperactivity disorder, and behavioral problems (1–3).
Renal angiomyolipomas (AMLs) occur in∼80% of patients (9); kidney disease is the leading cause
of death in adults with TSC (10). TSC is complex and highly varied (Figure 1) necessitating careful
coordination of care, which is lacking for most patients in the UK. Some TSC manifestations
are rarer; e.g., subependymal giant cell astrocytoma (SEGA) occurs in around 20–24% of patients
(11, 12) (Figure 2).
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FIGURE 1 | Network Diagram showing primary organ systems affected for
each patient from a retrospective cohort analysis of UK TSC patient data
(n = 324); sourced from the Clinical Practice Research Datalink (CPRD), linked
to secondary care data from Hospital Episode Statistics (HES) database, and
the Office for National Statistics (ONS) mortality register (Reproduced with
permission from Eur J Paediatr Neurol) (7).
Themajor unsolved problem in TSC is refractory epilepsy and
TSC-associated neuropsychiatric disorders (TAND); of which
preliminary evidence suggests refractory epilepsy is a major
cause (13–15).
TSC, like other complex rare diseases, is a major burden to
patients, families and healthcare systems. Optimizing care will
alleviate some of this while waiting for medical research to deliver
a cure.
Classically, a clinical diagnosis of TSC is made by identifying
major and minor features (Table 1) (1, 16). With wider
availability of genetic testing, identification of pathogenic
mutations in TSC1 or TSC2 is now sufficient to establish a
diagnosis, regardless of the presence of clinical features (1, 16),
and is particularly useful in confirming a suspected diagnosis,
as many clinical TSC manifestations are infrequent in young
patients (1, 16).
The approval of the mTORC1 inhibitor—everolimus—
for the treatment of AMLs, SEGA, and refractory epilepsy
represents a significant advance in the potential management
of the disease (17–19). Whilst not licensed in Europe, the
Federal Drugs Agency (FDA) have also approved sirolimus
for use in pulmonary lymphangioleiomyomatosis (LAM) (18).
Refractory seizures adversely affect early development (20).
Furthermore, appropriate early treatment of infantile spasms
with vigabatrin has been shown to reduce the long-term impact
of the neurological and neuropsychiatric aspects of TSC on
patients (13, 14).
A retrospective UK cohort study linking Clinical Practice
Research Datalink (CPRD) to Hospital Episode Statistics (HES)
data identified 334 patients with TSC revealed a much lower
frequency of complications than would be expected from
previous research; the disparity possibly reflecting under-
recognition, and hence suggestive of inadequate medical care (7).
It is clear from these findings, and the observation that many
new patients referred to TSC clinics have never had holistic
systematic monitoring, that many patients receive inadequate
care. In the UK, about 1000 TSC families are known to the
UK Tuberous Sclerosis Association, known as the TSA (Patient
organization), and a similar number (usually the same families)
attend UK specialist TSC clinics. Therefore, in most other cases,
the quality of care delivered is unknown.
Given the range of organ systems affected by TSC, its
treatment requires coordination across a number of medical
specialties over a patient’s lifetime (Table 2). Currently in the
UK, 16 centers host specialist TSC clinics—but most UK TSC
patients are not currently managed within them. These specialist
clinics have often been founded by enthusiastic clinicians but are
frequently inadequately funded.
The transition from pediatric to adult services can be
particularly challenging in the absence of a systematic service. In
Wales, a specialist TSC clinic that has been established through a
partnership, between a pharmaceutical company and the NHS,
awaits the development of a fully sustainable commissioning
model. In Northern Ireland, a TSC clinic has been running
since 1995, and directly reviews the majority of TSC patients in
the region.
In the UK, specialized service specifications are in place
for adults and children with genetic disorders such as
cystic fibrosis and inherited metabolic disorders. These are
funded by NHS England, the Department of Health, Social
Services and Public Safety in Northern Ireland, and Welsh
Health Specialized Services Committee in Wales. However,
no similar service or service specification is yet available for
TSC patients.
We propose a comprehensive, holistic model of care—to
manage patients that present with a range of manifestations,
requiring specialist management from a wide range of specialties
(Figures 1, 2).
REVIEW OF INTERNATIONAL GUIDELINES
ON TSC SURVEILLANCE AND
MANAGEMENT
The 2012 consensus statement on TSC surveillance and
management, together with UK guidelines published this year
make a number of recommendations for patient screening (1, 16,
21), with additional recommendations specific to AML, SEGA,
LAM, and TSC-related epilepsy reported in disease-specific
guidelines (22–24). A summary of the UK clinical guidelines,
targeted at patients and general physicians has been made
available by the UK TSA (25).
Additional baseline investigations to assess the extent of
disease and organ involvement (Table 3), play an important role
in guiding later treatment decisions.
The treatment and long-term surveillance needs (Table 4) (16)
should be determined, based on the extent of disease at baseline,
and tailored to the patient.
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FIGURE 2 | Disease Manifestations of TSC Reported at Baseline in TOSCA* Participants (n = 2,093) (Reproduced with permission of TOSCA consortium, presented
at The International TSC research Conference Tokyo 2018).
RECOMMENDATIONS FOR THE DELIVERY
OF SERVICES FOR TSC PATIENTS
A “hub and spoke” model of care is proposed, with a
central network of TSC-centers, co-ordinated by specialists, and
supported by a regional network of clinicians, that offer access to
a comprehensive set of TSC-related specialist services. Hospital
specialists should work collaboratively with patients, their
families and their community doctors (General Practitioners
or general physician) to provide support and advice and a
pathway for dealing with problems that need specialist care. Since
holistic care of TSC patients requires input from many different
specialties, treatment of TSC patients should be discussed within
the regional network by a multidisciplinary team (MDT), with
the aim of ensuring that each TSC patient and their family have a
tailored care plan to manage current disease manifestations, and
surveillance for future TSC manifestations.
To achieve this, Specialist TSC services should ensure:
• Diagnosis: Patients with TSC are identified by clinical
evaluation and/or genetic testing.
• Surveillance: Provision of multi-disciplinary evaluation–
through alignment with regional genetic services (for genetic
counseling to patients and their families), and with other
clinical specialties to ensure access to appropriate care for
all patients.
• Treatment: The appropriate access and use of TSC therapies.
• Safe transition from pediatric to adult care.
• Information and Support: Collaboration with
patients/family and other organizations to provide access to
TSC-specific information.
• Research: Facilitate patients and their families to become
involved in relevant research projects.
Regional TSC clinics should be responsible for the diagnosis
of patients with TSC, and the provision of routine care and
support for patients and their families. Regional clinics should
be supported by a dedicated TSC specialist coordinator, who
has responsibility for coordinating the service, ensuring timely
surveillance, and coordinating care between different specialist
services, developing individualized plans for patient follow-up,
and ensuring continuity of care for TSC patients transitioning
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TABLE 1 | Major and minor clinical manifestations of tuberous sclerosis
complex (1).
MAJOR FEATURES
Hypomelanotic macule (≥3, at least 5mm in diameter)
Angiofibroma (≥3) or fibrous cephalic plaque
Ungual fibroma (≥2)
Shagreen patch
Multiple retinal hamartomas
Cortical dysplasias*
Subependymal nodules
Subependymal giant cell astrocytoma
Cardiac rhabdomyoma
Lymphangioleiomyomatosis
Angiomyolipoma (≥2)
MINOR FEATURES
“Confetti” skin lesions
Dental enamel pits (>3)
Intraoral fibromas (≥2)
Retinal achromic patch
Multiple renal cysts
Non-renal hamartomas
*Cortical dysplasias includes tubers and cerebral white matter radial migration lines.
TABLE 2 | A wide range of healthcare services are involved in the diagnosis,
management, and treatment of the various manifestations of TSC. These include:
• Primary care
• Pediatrics/Community pediatrics
• Genetics
• Diagnostic radiology
• Interventional radiology
• Surgery
• Cardiology
• Respiratory medicine
• Nephrology
• Dermatology
• Neurology/Pediatric neurology
• Neurosurgery
• Oncology
• Fetal medicine
• Urology
• Ophthalmology
• Psychiatry
• Psychology
• Child, adolescent, and adult
learning disability psychiatry
to adulthood. Alongside this, linking regional clinics with TSC
patient support groups (e.g., in the UK, the Tuberous Sclerosis
Association (TSA), is vital to ensure that patients and their
families receive comprehensive support). Regional clinics are in
an ideal position to gather clinical and prevalence data tomonitor
needs locally and facilitate future research.
To allow regional TSC clinics to fulfill this pluripotent
role, they need to offer or have access to a range of core
services, including:
• Genetic Testing and Genetic Counseling.
• Neurology and Neuroimaging.
• Nephrology, Urology, General and Interventional
Radiology services.
• Clinical Psychology, Psychiatry, and
Developmental Pediatrics.
• Collaboration with patient/family organizations.
• Collaboration with patient’s community physician
(General Practitioner).
TABLE 3 | Surveillance and management recommendations for newly diagnosed
or suspected TSC (16, 21).
Organ system or
specialty area
Recommendation
Genetics • Obtain three-generation family history to assess for
additional family members at risk of TSC.
• Offer genetic testing for family counseling or when TSC
diagnosis is in question but cannot be clinically confirmed.
Brain • Perform magnetic resonance imaging (MRI) of the brain to
assess for the presence of tubers, subependymal nodules
(SEN), migrational defects, and subependymal giant cell
astrocytoma (SEGA).
• Evaluate for TSC-associated neuropsychiatric disorder
(TAND), using the TAND checklist (26).
• During infancy, educate parents to recognize infantile
spasms, even if none have occurred at time of first diagnosis
• Obtain baseline routine electroencephalogram (EEG). If
abnormal, especially if features of TAND are also present,
follow-up with a 24-h video EEG to assess for subclinical
seizure activity.
Kidney • Obtain MRI of the abdomen to assess for the presence of
angiomyolipoma and renal cysts.
• Screen for hypertension by obtaining an accurate blood
pressure.
• Evaluate renal function by determination of glomerular
filtration rate (GFR).
Lung • Perform baseline pulmonary function testing (pulmonary
function testing and 6-min walk test) and high-resolution
chest computed tomography (HRCT), even if asymptomatic,
in patients at risk of developing lymphangioleiomyomatosis,
typically females 18 years, or older. Adult males, if
symptomatic, should also undergo testing.
• Provide counsel on smoking risks and estrogen use in
adolescent and adult females.
Skin • Perform a detailed clinical dermatologic inspection/exam.
Teeth • Perform a detailed clinical dental inspection/exam.
Heart • Consider fetal echocardiography to detect individuals with
high risk of heart failure after delivery when rhabdomyomas
are identified.
• via prenatal ultrasound.
• Obtain an echocardiogram in pediatric patients, especially if
younger than 3 years of age.
• Obtain an electrocardiogram (ECG) in all ages to assess for
underlying conduction defects.
Eye • Perform a complete ophthalmologic evaluation, including
dilated fundoscopy, to assess for retinal lesions, and visual
field deficits.
The roles of each of these core services is summarized in Table 5.
Where regional centers are unable to provide a core service, there
should be a clear pathway through which that service can be
accessed. Furthermore, regional centers should also have access
to the necessary facilities to cater for the specific needs of TSC
patients. For example, TSC-related intellectual impairment and
autistic spectrum disorder may necessitate that surveillance brain
and renal imaging be performed under general anesthetic. This
requires co-ordination of such procedures in an appropriate day-
unit, or via a formal inpatient admission, with the support of
specialized pediatric and adult anesthetists.
In addition to the “core” services, in order to provide
comprehensive treatment to TSC patients, regional TSC centers
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TABLE 4 | Surveillance and management recommendations for patients already diagnosed with definite or possible TSC (16, 21).
Organ system or
specialty area
Recommendation
Genetics • Offer genetic testing for family counseling or when TSC diagnosis is in question but cannot be clinically confirmed.
Brain • Obtain brain MRI 1–3 yearly in asymptomatic TSC patients aged under 25 years to monitor for new occurrence of SEGA.
• Patients with asymptomatic large/growing SEGA, with or without ventricular enlargement should undergo MRI scans more frequently
and the patients and their families should be educated regarding the potential of new symptoms. Patients with asymptomatic SEGA
in childhood should continue to be imaged periodically as adults to ensure there is no growth.
• For acutely symptomatic SEGA, neurosurgical resection, with or without cerebral spinal fluid diversion (shunt) is advocated.
• For asymptomatic but growing SEGA, either surgical resection or medical treatment with mTOR inhibitors may be used. In
determining the best treatment option, discussion should include the risks of complication and adverse outcomes, cost, length
of treatment, and potential impact on TSC-associated comorbidities.
• At least annual screening for TAND features at each clinical visit, using the TAND checklist (26). Comprehensive formal evaluation for
TAND at key developmental time points: infancy (0–3 years), preschool (3–6 years), primary school (6–9 years), adolescence (12–16
years), early adulthood (18–25 years), and as needed thereafter. Management strategies should be based on the TAND profile of each
patient and should be based on evidence-based good practice guidelines/practice parameters for individual disorders (e.g., autism
spectrum disorder, attention deficit hyperactivity disorder, anxiety disorder). Always consider the need for an individual educational
program (IEP). Sudden change in behavior should prompt medical/clinical evaluation to look at potential medical causes (e.g., SEGA,
seizures, renal disease).
• Routine electroencephalograph (EEG) should be performed in individuals with known or suspected seizure activity. The frequency
of routine EEG should be determined by clinical need rather than a specific defined interval. Prolonged video EEG, 24 h or longer, is
appropriate when seizure occurrence is unclear or when unexplained sleep, behavioral changes, or other alteration in cognitive or
neurological function is present.
• Vigabatrin is the recommended first-line therapy for infantile spasms. ACTH can be used if treatment with vigabatrin is unsuccessful.
Anticonvulsant therapy of other seizure types in TSC should generally follow that of other epilepsies.
• Epilepsy surgery should be considered for medically refractory TSC patients, but special consideration should be given to children
at younger ages experiencing neurological regression and is best if performed at epilepsy centers with experience and expertise
in TSC.
Kidney • Obtain MRI of the abdomen to assess for the progression of angiomyolipoma and renal cystic disease every 1–3 years throughout
the lifetime of the patient.
• Assess renal function (including determination of glomerular filtration rate) and blood pressure at least annually.
• First-line therapy for renal AMLs presenting with acute hemorrhage is embolization followed by corticosteroids, with nephrectomy to
be avoided if possible.
• First-line therapy for asymptomatic, growing AMLs measuring larger than 3 cm in diameter is treatment with an mTOR inhibitor.
Selective embolization or kidney-sparing resection are acceptable second-line therapy for asymptomatic AMLs.
Lung • Perform clinical screening for lymphangioleiomyomatosis (LAM) symptoms, including exertional dyspnoea and shortness of breath,
at each clinic visit. Counseling regarding smoking risk and estrogen use should be reviewed at each clinic visit for individuals at risk
of LAM.
• Obtain HRCT every 5–10 years in asymptomatic individuals at risk of LAM if there is no evidence of lung cysts on their baseline
HRCT. Individuals with lung cysts detected on HRCT should have annual pulmonary function testing (pulmonary function testing and
6-min walk) and HRCT interval reduced to every 2–3 years.
• mTOR inhibitors may be used to treat LAM patients with moderate to severe lung disease or rapid progression. TSC patients with
LAM are candidates for lung transplantation but TSC comorbidities may impact transplant suitability.
Skin • Perform a detailed clinical dermatologic inspection/exam annually.
• Rapidly changing, disfiguring, or symptomatic TSC-associated skin lesions should be treated as appropriate for the lesion and clinical
context, using approaches such as surgical excision, laser(s), or possibly topical mTOR inhibitor.
• Facial angiofibromas (And some other skin lesions) respond to systemic or topical mTOR inhibitor; which can prevent more severe
disease later if started early (27, 28).
Teeth • Perform a detailed clinical dental inspection/exam at minimum every 6 months and panoramic radiographs by age 7, if not performed
previously.
• Symptomatic or deforming dental lesions, oral fibromas, and bony jaw lesions should be treated with surgical excision or curettage
when present.
Heart • Obtain an echocardiogram every 1–3 years in asymptomatic pediatric patients until regression of cardiac rhabdomyomas is
documented. More frequent or advanced diagnostic assessment may be required for symptomatic patients.
• Obtain electrocardiogram (ECG) every 3–5 years in asymptomatic patients of all ages to monitor for conduction defects. More
frequent or advanced diagnostic assessment such as ambulatory and event monitoring may be required for symptomatic patients.
Eye • Annual ophthalmologic evaluation in patients with previously identified ophthalmologic lesions or vision symptoms at the baseline
evaluation.
• NB this frequency may not be necessary for most patients and the recommendation may be changed in the forthcoming 2019
revision of the International TSC Clinical Guidelines.
• More frequent assessment, including those treated with vigabatrin, is of limited benefit and not recommended unless new clinical
concerns arise.
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TABLE 5 | TSC clinic—core services.
Core Services Role
1. Genetic testing and counseling • Diagnostic opinion and management advice, including perinatally.
• Arrange genetic testing, when indicated, and aid with interpretation of results.
• Cascade genetic testing to identify asymptomatic disease in parents and relatives & stratify
risk of developing TSC manifestations.
• Discuss options for prenatal & pre-implantation genetic diagnosis.
2. Neurology and neuroradiology • Access to pediatric and adult neurology services with specific epilepsy expertise, including
epilepsy, and learning disability nurses.
• Access to Neurophysiological tests including routine electroencephalogram (EEG) for patients
with suspected or known seizure activity, and video-telemetry.
• Access to Neuroradiological investigations: Baseline brain MRI (including MRI under general
anesthesia where required): children and young adults with TSC should have a surveillance
MRI every 2–3 years.
3. Nephrology, Urology, General, and Interventional Radiology • Access to pediatric and adult nephrology, urology and interventional radiology services.
• Radiological monitoring should include baseline and 1–3 yearly surveillance MRI (including
under general anesthesia where required), depending on the presence and size of lesions.
• MRI is the optimal renal imaging modality; CT or ultrasound may be acceptable alternatives
in some circumstances. Where possible, 3D Volumetric analysis for AML to monitor change
in lesions.
4. Clinical Psychology, Psychiatry and Developmental Pediatrics • Assess and diagnose intellectual, behavioral, and psychiatric conditions associated with TSC.
• Monitoring should include baseline evaluation of cognition, regular screening for TAND (or
more frequently if required), and comprehensive formal evaluation of TAND at key
developmental milestones (21).
would also need to have access to additional specialist support
services, including Dermatology, Respiratory, Cardiology,
Neuropsychiatry, and Obstetrics/Gynecology. The role of
each of these additional services in relation to TSC patients is
summarized in Table 6.
TSC Clinics need access to highly specialized services, of
which there are four in the UK, including for Pulmonary LAM,
Pediatric epilepsy surgery, Neurosurgery & Neuro-oncology and
Neuropsychiatric services (summarized in Table 7).
In addition to ensuring access to appropriate services, there
are key responsibilities for the regional centers in ensuring
holistic care for TSC patients and their families.
Regional services need to ensure provision of the supportive
care needed by patients and their families, including referral for
individualized education plans for patients, genetic counseling
for family members, and ongoing support for both the patient
and their family from a patient association.
There is a need to monitor patient movement through the
service to ensure that all patients are offered appropriate, regular
surveillance and timely follow-up. Patients should be offered the
most up-to-date, evidence-based surveillance, and those patients
with multiple complications of TSC should attend joint clinics,
or have the monitoring of different manifestations performed in
a single session (e.g., combined surveillance/monitoring of SEGA
and renal AML through a coordinated MRI scan of both brain &
renal tract—particularly where a general anesthetic is required to
achieve the imaging), in order to minimize individual patients’
time in hospital. Such efforts would not only help to reduce the
costs of patient monitoring but help to improve patients’ and
careers’ experience of care, and their quality of life.
TSC regional centers should ensure that the service is aligned
with National guidelines such as those published by NICE or
the Renal Association on how to manage transitional care for
patients moving from pediatric to adult services, with bespoke
plans drawn up for individual patients where necessary.
TSC centers and networks should collaborate with the current
available networks of local/community services (e.g., Community
pediatricians and mental health services) to optimize care and
minimize cost.
Pediatric and adult TSC centers, if not co-located, need to
collaborate proactively to ensure safe transition of care from
children’s’ to adult services. This is a time when patients are often
lost to follow up.
Finally, there is a need to audit the services offered to and
used by patients with TSC, so as to ensure that patients are
treated appropriately. A very helpful way to ensure that clinic
services develop into exactly what is needed by patients and
families is to audit services using PREMS (Patient reported
experience measures) (29) and PROMS (Patient reported
outcome measures) (30).
Regular review of services will help to identify any potential
opportunities for improved efficiency, as well as ensure that
patients are consistently screened and treated according to
best practice. With this aim, a national database should be
established to facilitate the coordination of care between centers,
auditing of services, planning of resource allocation, and TSC-
related research.
DISCUSSION
The rarity and heterogeneity of TSC presentations offers a
number of challenges to the implementation of best practice care;
treatment and follow-up is consequently frequently fragmented,
disjointed, and suboptimal.
There is a need to improve TSC management to ensure
patients have early access to appropriate treatment and
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TABLE 6 | TSC clinic—additional services.
Additional services Role
Dermatology • All patients with TSC should have an annual review of their skin, carried out in the regional TSC clinic.
• Patients should be referred for specialist dermatological advice when required.
Respiratory • A high-resolution computed tomography (HRCT) of the chest should be performed at 18–21 years, particularly in post-pubertal
females, who are at higher risk of developing pulmonary LAM.
• In asymptomatic patients with no sign of LAM on the HRCT chest, scanning should be repeated to screen for new onset disease
every 5–10 years.
• Patients with pulmonary LAM should undergo regular pulmonary function tests, assuming the patient is able to cooperate. HRCT
should be repeated at 2–3-years intervals to monitor for changes in known lesions. Patients with progressive or complex disease,
should be referred to, or discussed with, the LAM highly specialized service based in Nottingham (Table 6).
Cardiology • Affected infants and children should receive a baseline echocardiogram, and electrocardiogram (ECG) if any new-onset
TSC-related symptoms are identified.
Neuropsychiatry • Patients with TSC-related psychiatric comorbidities frequently require treatment with psychotropic medications. Regional centers
should have input into identifying the most appropriate treatment for these patients, as their care may be complicated by a high rate
of comorbid illness, poor response and a high risk of adverse side effects, and potential drug interactions due to polypharmacy.
Pregnancy • All women of reproductive age should be offered contraceptive advice.
• Women with a pregnancy where the fetus is at risk of/known to have TSC should be referred to specialized fetal medicine services
to consider invasive testing. In the absence of an identifiable mutation, monitoring for cardiac rhabdomyomas and/or other genetic
testing can occur.
• All women should be offered pre-pregnancy counseling, including genetic counseling.
• During pregnancy women should be sign-posted to antenatal care in a high-risk combined maternal medicine service.
TABLE 7 | Highly specialized centers for TSC in the UK.
Highly specialized centers for TSC Role
Pulmonary LAM • Patients with TSC and symptomatic pulmonary LAM should in the first instance be assessed in their local respiratory
center. If appropriate, they may be referred to a specialist center (e.g., in England, this is the LAM center at Nottingham
University Hospital Trust, as described in the NHS England service specification).
Pediatric epilepsy surgery • Children with TSC-related drug-resistant epilepsy should be referred to an NHS England commissioned Children’s
Epilepsy Surgery Service (CESS) center for consideration of intervention (Great Ormond Street Hospital or King’s College
Hospital in London, services are also located in Bristol, Birmingham, and Manchester/Liverpool).
Neurosurgery and neuro-oncology • Patients with SEGA should have their overall management overseen by the specialist neurosurgical and
neuro-oncological service.
Neuropsychiatry • Complex neuropsychiatric presentations should be considered for referral to NHS England-commissioned centers (in
Manchester, Newcastle, or London) to access diagnostic assessments, and management advice for Autism Spectrum
Disorder and associated neuropsychiatric conditions.
preventive measures—both to minimize long-term effects of
TSC where possible, and to support a frequently vulnerable
patient group and their families. In particular, there are three
elements that are both essential for the success of a TSC clinic,
yet frequently missing. These include dedicated neuropsychiatric
input, access to CT/MRI imaging under general anesthetic,
and perhaps most importantly, a dedicated specialist TSC co-
ordinator. A mechanism to deliver optimal care is essential if
patients are to gain the best outcomes; including monitoring and
intervention for SEGA, renal AMLs, LAM, and TAND, and early
improvement in refractory epilepsy.
Hepatic lesions are common in TSC but very rarely
cause any clinical problems (31). They do not need to be
regularly monitored.
The primary physician of a patient is usually their
general pediatrician or, in adults, their general practitioner
or general physician. They may delegate responsibility for
holistic management of TSC care to a hospital specialist
but remain responsible for other aspects of their patient’s
care, so that collaboration and good communication
is essential.
Finally, it should be acknowledged that optimal management
of TSC is a field of active research and new recommendations
will continue to be made. For example, It is now recognized that
regular surveillance EEGs in infants can identify infants who are
about to begin having seizures (32, 33). Emerging evidence from
the Epistop trial and historic case series suggest starting therapy
promptly or before the onset of clinical seizures, may markedly
improve outcomes (13, 14). Similarly, genetic testing cannot yet
be used to accurately predict an individual’s prognosis, only the
average risk in a group, but this is likely to change in the near
future (9, 34).
We advocate that specialist expertise be provided by
centralized TSC “hubs,” with routine patient management
coordinated centrally and undertaken in regional TSC networks
to facilitate optimal resource use and improve the comprehensive
care of TSC patients. The TSC hub-and-spoke model will form a
coordinated care network, that will also provide a structure to
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facilitate the education of health care professionals and affected
families, and to facilitate TSC research. This model for TSC care
may also serve as a blueprint for improving the quality of care for
patients with other rare diseases in evolving, ever more efficient,
healthcare services.
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